Provided by Tiger Trade Technology Pte. Ltd.

DiaMedica Therapeutics Inc.

6.52
0.0000
Post-market: 6.39-0.1300-1.99%16:17 EDT
Volume:84.66K
Turnover:549.54K
Market Cap:351.31M
PE:-9.11
High:6.57
Open:6.53
Low:6.32
Close:6.52
52wk High:10.42
52wk Low:5.14
Shares:53.88M
Float Shares:28.20M
Volume Ratio:0.74
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7157
EPS(LYR):-0.7000
ROE:-114.62%
ROA:-64.12%
PB:9.16
PE(LYR):-9.31

Loading ...

DiaMedica Q2 FY26 Net Loss Widens to $10.14 Million; R&D Expenses Climb to $8.15 Million

Reuters
·
Aug 11

DiaMedica Q2 Net Loss Widen Less than Expected

Reuters
·
Aug 11

DiaMedica Therapeutics Q2 Pretax Profit USD -10.132 Million

THOMSON REUTERS
·
Aug 11

DiaMedica Therapeutics Inc Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 07

DiaMedica Therapeutics Updates Financial Calendar for Quarterly Results Release and Conference Call

Reuters
·
Aug 05

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

THOMSON REUTERS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 25

DiaMedica Therapeutics announces dosing of first two patients in DM199 study

TIPRANKS
·
Jun 24

DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial

MT Newswires Live
·
Jun 23

DiaMedica doses first patients in Phase 2 fetal growth restriction trial of DM199

Reuters
·
Jun 23

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of Dm199 for the Treatment of Fetal Growth Restriction

THOMSON REUTERS
·
Jun 23

BUZZ-DiaMedica rises after FDA feedback clears path for preeclampsia drug study

Reuters
·
Jun 16

DiaMedica Therapeutics receives written response from FDA on DM199

TIPRANKS
·
Jun 16

DiaMedica initiates rat PK study to address FDA nonclinical request for DM199 preeclampsia program

Reuters
·
Jun 16

DiaMedica Therapeutics - Initiates Rat Pharmacokinetic and Activity Study of Dm199

THOMSON REUTERS
·
Jun 16

DiaMedica Receives FDA Feedback on Dm199 Preeclampsia Nonclinical Program

THOMSON REUTERS
·
Jun 16

DiaMedica Therapeutics - to Submit Rat Pk Study Data to FDA Upon Completion

THOMSON REUTERS
·
Jun 16

DiaMedica Therapeutics to present at Jefferies Global Healthcare Conference 2026

Reuters
·
May 28

DiaMedica Therapeutics shareholders re-elect seven directors at annual meeting

Reuters
·
May 22